MedTrace Logo

Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)

NCT03713359 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 756

Last updated 2018-10-19

No results posted yet for this study

Summary

The study is conducted to evaluate the safety and Immunogenicity of Measles-Rubella combined vaccine MRVAC produced by POLYVAC (phase 3) on Vietnamese volunteers and to demonstrate non-inferiority on the immunogenicity of MRVAC in comparison to MR vaccine produced by Serum Institute, India.

Conditions

  • Signs and Symptoms

Interventions

BIOLOGICAL

Trial arm (MRVAC)

Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine

BIOLOGICAL

Control arm

Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine

Sponsors & Collaborators

  • Vietnam Military Medical University

    collaborator OTHER

  • Center for Research and Production of Vaccines and Biologicals, Vietnam

    lead OTHER_GOV

Principal Investigators

  • Dinh H. Duong, Ph.D · Epidemiology department - Vietnam Military Medical University.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-07-31
Completion
2016-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713359 on ClinicalTrials.gov